Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Salk Institute for Biological Studies

https://www.salk.edu/

Latest From Salk Institute for Biological Studies

Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx

NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.

Deals Research and Development Strategies

Precision Medicine In Psychiatry: Astellas Joins Search For Biomarkers, Drug Targets

Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.

Research and Development Strategies Clinical Trials

Scientists Marched To Protect NIH Grants, But Where Was Pharma?

Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.

Innovation Research and Development Strategies

Takeda-Zydus Enter Increasingly Crowded Chikungunya Fray

Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.

Research & Development Infectious Diseases
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register